Genexine Life Sciences (CEO Ko Kwangyeon) announced on January 16 that it has selected DNA- and mRNA-based "personalized anti-cancer nucleic acid vaccines" as a core strategic pipeline for the company and has officially begun development.
The company explained that this strategy is based on the experience of its subsidiary VGXI, whose personalized anti-cancer DNA vaccine was successfully used in a U.S. Food and Drug Administration (FDA) approved clinical trial. Recently in the United States, as a patient who received the vaccine continued to show favorable progress during treatment, the medical team, with the patient’s consent, inquired whether VGXI, the original manufacturer, could produce an additional small batch of the vaccine.
This vaccine was produced at VGXI’s cGMP (current Good Manufacturing Practice) facility and supplied for FDA-approved clinical research. Genexine Life Sciences stated that if an official production request is made by a relevant company, they are capable of providing rapid manufacturing support, thereby demonstrating their practical capabilities in the field of personalized vaccines.
A Genexine Life Sciences official stated, “This case demonstrates that VGXI already has practical experience in manufacturing personalized anti-cancer nucleic acid vaccines in a GMP environment and supplying them for FDA-approved clinical trials,” adding, “This will serve as an important technological foundation for Genexine’s personalized anti-cancer vaccine development strategy.”
The company further announced plans to continuously share specific achievements and progress obtained through collaborations with partners possessing cancer information sequencing and AI technologies, thereby enhancing transparency in the development process and building a globally competitive anti-cancer vaccine ecosystem.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
